Abstract:Objective:To explore the safety and efficacy of Propafenone in terminating paroxysmal supraventricular tachycardia (PSVT) in children and analyze the factors influencing the effectiveness.Methods:A retrospective study was conducted on 169 PSVT children treated with Propafenone in the Department of Pediatric Cardiology, Heart Center, the First Hospital of Tsinghua University from September 2014 to October 2021.There were 118 boys and 51 girls with an average age of (2.84±2.91) years (age range: 14 days-13 years). According to age, they were divided into ≤ 1-year-old group, >1-3-year-old group, >3-7-year-old group, and >7-year-old group.Mea-surement data were compared between groups using t-test and Mann- Whitney U test.Counting data were analyzed by χ2 test. Results:Among the 169 children with PSVT, 65 cases (38.5%) were below 1 year old, 47 cases (27.8%) were >1-3 years old, 40 cases (23.7%) were >3-7 years old, 17 cases (10.1%) were above 7 years old.About 24 cases (14.2%) were combined with congenital heart disease.A total of 153 cases (90.5%) had nonspecific symptoms at the first visit.A total of 4.1% (7/169 cases) were complicated with tachycardia-induced cardiomyopathy, and their left ventricular ejection fraction increased from (44.0±4.0)% to (53.7±6.9)% after successful control of PSVT ( t=-4.700, P=0.003). The complete termination of PSVT by intravenous Propafenone was achieved in 125 of 169 cases (74.0%, 125/169 cases). The complete termination rate after multiple times of administration (74.0%) was significantly higher than that after the first intravenous injection (53.3%, 90/169 cases) ( χ2=15.657, P<0.001). There was a significant difference regarding the complete termination rate between children ≤1 year old (60.0%, 39/65 cases) and those >1 year old (82.7%, 86/104 cases) ( χ2=10.696, P=0.001). For children ≤1 year old, 1.5 mg/kg Propafenone (51.1%, 23/45 cases) showed better efficacy for PSVT termination than 1.0 mg/kg Propafenone (20.0%, 4/20 cases) ( χ2=5.519, P=0.019). For children >1 year old, there was no significant diffe-rence between 1.5 mg/kg and 1.0 mg/kg Propafenone groups (57.9% vs.62.1%) ( χ2=0.180, P=0.671). The adverse reaction rate of intravenous Propafenone was 9.5% (16/169 cases). One case presented with severe hypotension, which occurred in a child with right cardiac insufficiency with tricuspid valve depression; 15 cases showed abnormal cardiac conduction and recovered spontaneously in a short time.There was no deterioration of cardiac function in children with mildly to moderately reduced cardiac function. Conclusions:It is relatively safe and effective to terminate PSVT in children with intravenous Propafenone.The complete termination rate is 74.0%, which is related to age, dose and times of administration.Despite of low incidence of side effects, Propafenone should not be used to treat PSVT with cardiac function which is significantly impaired or unclear secondary to persistent tachycardia.Special attention should be paid to cardiac function deterioration in these patients.

Clinical Efficacy and Safety of Homemade Adenosine in Treatment of Paroxysmal Supraventricular Tachycardia

The Clinical and Electrophysiological Effects of Adenosine Triphosphate in Patients with Supraventricular Tachycardia

Comparing methods of adenosine administration in paroxysmal supraventricular tachycardia: a pilot randomized controlled trial

Electrophysiologic Study of the Effects of Esmolol Hydrochloride Produced by Our Country

[Efficacy and Safety of Ibutilide for Conversion of Atrial Fibrillation/flutter].

Comparison of Converting Efficacy and Safety of Intravenous Ibutilide and Propafenone in Chinese Patients with Atrial Fibrillation and Atrial Flutter

Evaluation of adenosine triphosphate in emergency cardioversion of paroxysmal supraventricular tachycardia in children

Effect of Oral Propafenone on Reversing Paroxysmal Atrial Fibrillation with No Rheumatic Disease

Combined modified Valsalva maneuver with adenosine supraventricular tachycardia: A comparative study

Inducibility and ablation of atrial fibrillation from non-pulmonary vein foci in patients with paroxysmal atrial fibrillation

Systematic Evaluation of Propafenone and Verapamil in the Treatment of Paroxysmal Supraventricular Tachycardia

Radiofrequency Catheter Ablation For Treatment Of Paroxysmal Supraventricular Tachycardia In Children

Clinical features and treatment of paroxysmal supraventricular tachycardia in children

Value of the Adenosine Test for Diagnosis of Dual AV Nodal Physiology in Patients with AV Nodal Reentrant Tachycardia

Effects of adenosine on patients with premature ventricualr contractions originating from the ventricle outflow tract

Safety of adenosine for pediatric tachyarrhythmia treatment in the emergency department: a multi-hospital 10-year cross-sectional study

Efficacy and Influencing Factors of Propafenone in Acute Treatment of Paroxysmal Supraventricular Tachycardia in Children

A Retrospective Study of the Elderly Patients with Paroxysmal Supraventricular Tachycardia Treated with Drug

Observation of Guan-fu base A (GFA) hydrochloride injection in treatment of paroxysmal supraventricular tachycardia

Clinical and experimental study of DL-tetrahydropalmatine effect in the treatment of supraventricular arrhythmia

Efficacy and safety of modified Valsalva maneuver for treatment of paroxysmal supraventricular tachycardia: a meta-analysis